Abstract: Objective To evaluate the treatment efficacy and safety of telbivudine (LDT) and tenofovir (TDF) for preventing mother-to child transmission in HBV DNA-positive pregnant women at their middle and late stages of pregnancy.Methods The literatures published by Chinese scholars from January 2010 to August 2019 on the comparative application of LDT and TDF to prevent HBV mother-to-child transmission in pregnant women at the middle and late stages of pregnancy were retrieved from CNKI, Wan Fang, Weipu, Pubmed, and CBM. meta analysis was performed on these studies using Rev. Man 5.0 software.Results One randomized control trial (RCT) and 9 cohort studies were recruited, with a total of 897 and 716 cases of pregnant women in LDT group and TDF group, respectively. The numbers of HBsAg positive cases at birth in these two groups were 11 and 2, respectively [OR=1.66, 95 % CI(0.76, 3.62), P=0.21]. There were no significant differences in the neonatal birth weight [OR=17.83, 95 % CI(-39.47±75.14), P=0.54], and the numbers of neonatal malformation [6(0.67 %) vs 1(0.14 %)].Conclusion Both LDT and TDF treatments for the middle and late stages of pregnant women with high HBV DNA load reduce the risk of mother-to-child transmission of HBV effectively and safely.

Key words: Telbivudine, Tenofovir, Blocking mother-to-child transmission, meta-analysis